As one of the strategies of melanoma immunotherapy, the application of immune checkpoint inhibitors, in particular, antibodies of programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1), are widely used to enhance the immune response and induce cancer attack, but they only exhibit effectiveness on a minority of patients [58]. This evidence concerns the gene PDCD1 and cancer.